Psychopharmacologic Drugs Advisory Committee

March 23, 2006


New Drug Application (NDA) 20-717/ S -019, trade name Provigil® Tablets, Cephalon, Inc., proposed indication is for treatment of attention-deficit/ hyperactivity disorder (ADHD).



ERRATA to the Transcript



On page 47, line 1:       “the 0.7 would still be statistically significant  should read  “the 0.07 would still be statistically significant”



On page 51, line 7:  “that is with 1.5 million” should read “that is with 1,050,000”